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HIV-1 Vpr triggers NK cell-mediated lysis of infected cells by upregulating ULBP2, a ligand of the NKG2D
receptor, through activation of the ATR-mediated DNA damage response. Herein, we demonstrate that
Vpr augments ULBP2 expression on both infected and uninfected bystander cells during HIV-1 infection
of primary CD4+ T lymphocytes. Indeed, the frequency of uninfected bystander cells expressing high
levels of ULBP2 was elevated in a Vpr-dependent manner. Nevertheless, the same does not hold true for a
Vpr mutant that is not packaged into virions, suggesting the involvement of virion-associated Vpr in this
process. Additionally, we show that soluble Vpr has the ability to induce a DNA damage response and
to augment cell-surface ULBP2 upon transducing target cells, including T cells, conditions known to
promote NK cell-mediated killing. Overall, these ﬁndings suggest that Vpr could contribute to CD4+ T cell
loss by rendering uninfected bystander cells susceptible to NK cell-mediated killing.
& 2013 Elsevier Inc. All rights reserved.Introduction
Chronic immune activation and gradual depletion of CD4+ T
cells are the hallmarks of human immunodeﬁciency virus (HIV-1)
infection, which are thought to contribute to the progressive
deterioration of the host's immune response that ultimately
leads to acquired immune deﬁciency syndrome (AIDS). However,
despite extensive research efforts that spanned almost three
decades, the precise mechanisms underlying the progressive
depletion of CD4+ T cells continues to be one of the most
fundamental and debated issues of AIDS research. Both direct
and indirect mechanisms of cell killing have been proposed. For
instance, during in vitro infection of immortalized T cell lines, it is
direct killing of CD4+ T cells that prevails. In contrast, in more
physiological systems, such as ex vivo HIV-1 infection of lymphoid
tissues or lymph nodes from HIV-1 infected individuals, it is
primarily uninfected bystander CD4+ T cells that are killed (Finkel
et al., 1995; Jekle et al., 2003), underscoring the potentially important
contribution of this loss to the overall depletion of CD4+ T cells. Over
the years, several indirect mechanisms have been proposed to
contribute to the killing of uninfected bystander CD4+ T cells,
including those mediated by HIV-1-encoded proteins Tat, Nef,ll rights reserved.
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).gp120 or viral protein R (Vpr), since these viral proteins can induce
apoptosis of neighbouring uninfected cells upon their release from
infected cells (Varbanov et al., 2006). Moreover, HIV-1 defective
virus particles, which represent the majority of virions that are
released during productive infection (Dimitrov et al., 1993; Piatak
et al., 1993), have also been suggested to play a part in CD4+ T cell
loss either by interacting with uninfected bystander cells or/and
by transducing these cells (Esser et al., 2001; Herbeuval et al.,
2005; Richard et al., 2010). More recently, abortive HIV infections,
such as those occurring in nonpermissive resting CD4+ T cells,
were shown to activate proapoptotic and inﬂammatory responses
as a result of the sensing of incomplete reverse transcripts that are
accumulating in these conditions, thus contributing to the killing
of bystander cells (Doitsh et al., 2010).
The HIV-1 Vpr accessory protein can be found in vivo not only
as an intracellular or intravirion protein but also in an extracellular
soluble form. Indeed, Vpr is efﬁciently packaged into viral particles
via an interaction with the p6 domain of Gag (Bachand et al., 1999;
Lu et al., 1995) and can be detected as a soluble protein in the
serum and cerebrospinal ﬂuid of HIV-1-infected individuals
(Hoshino et al., 2007; Levy et al., 1994) as well as in the
extracellular medium of virus-producing cells in vitro (Xiao et al.,
2008). Importantly, the fact that recombinant soluble Vpr displays
natural-transducing properties on multiple cell types (Sherman
et al., 2002), suggests that Vpr could transduce uninfected bystan-
der cells not only as a defective virion-associated protein but also
as a secreted protein.
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promote a cell cycle arrest at the G2 phase when expressed alone or
in the context of HIV-1 infection (He et al., 1995; Jowett et al., 1995;
Re et al., 1995). Interestingly, soluble and virion-associated Vpr
molecules were also found to have the ability to induce a cell cycle
arrest (Hrimech et al., 1999; Poon et al., 1998; Sherman et al., 2002),
suggesting that Vpr could exert this biological activity on uninfected
bystander cells. Accumulating evidence indicates that Vpr-mediated
cell cycle arrest relies on the recruitment of a cullin-ring E3 ubiquitin
ligase, namely DDB1-CUL4A (VprBP also designated DCAF1) by Vpr,
and on the activation of a cellular DNA damage response (DDR)
initiated by the ataxia telangiectasia-mutated and Rad3-mutated
(ATR) kinase (review in (Romani and Cohen, 2012)). Indeed, expres-
sion of Vpr induces the phosphorylation of several effector molecules
regulated by ATR, including the checkpoint kinase 1 (Chk1) and the
histone 2A variant X (H2AX), and the formation of DNA repair foci
containing phosphorylated H2AX (γ-H2AX) and p53 binding protein
1 (53BP1) through a process that is dependent on the engagement
of DDB1-CUL4A (VprBP) (Belzile et al., 2010a; Lai et al., 2005;
Zimmerman et al., 2004).
Recently, we and others reported that activation of ATR by Vpr
leads to the augmentation of speciﬁc ligands of the activating
natural killer group 2, member D (NKG2D) receptor, which is
constitutively expressed on Natural Killer (NK) cells (Richard et al.,
2010; Ward et al., 2009). Indeed, ULBP2, a member of the human
cytomegalovirus UL16 binding protein (ULBP) family, was the most
predominantly upregulated NKG2D ligand (NKG2DL) during infec-
tion of primary CD4+ T cells with Vpr-proﬁcient virus. Paradoxi-
cally, increased expression of ULBP2 at the surface of infected cells
enhanced their recognition and killing by NK cells in a NKG2D-
dependent manner (Richard et al., 2010; Ward et al., 2009).
Importantly, laboratory-adapted as well as primary Vpr variants
from all HIV-1 groups were found to be sufﬁcient to enhance
ULBP2 expression and promote killing by NK cells (Pham et al.,
2011; Richard et al., 2010; Ward et al., 2009). Mechanistically, this
upregulation of ULBP2 at the surface of Vpr-expressing cells
correlated with an increased detection of ULBP2 transcripts,
suggesting that Vpr-mediated DDR was increasing ULBP2 expres-
sion at the transcriptional level (Richard et al., 2010; Ward et al.,
2009).
In light of the aforementioned ﬁndings and the fact that Vpr
could transduce target cells as a secreted protein or in association
with defective particles, we investigated in the present study
whether Vpr could mediate a similar biological activity on unin-
fected bystander cells as it does on infected ones. Herein, we
provide evidence that Vpr, as a secreted or virion-associated form,
contributes to the enhancement of ULBP2 expression on unin-
fected cells – a condition known to promote NK cell-mediated
killing – suggesting that it may participate in the depletion of
CD4+ T cells during HIV-1 infection.Results
HIV-1 upregulates ULBP2 in uninfected bystander cells in a Vpr-
dependent manner
To evaluate whether Vpr could upregulate ULBP2 in uninfected
bystander cells, we established a sensitive system to examine
ULBP2 expression in both infected and uninfected cells following
exposure of primary CD4+ T cells to HIV-1 lacking (ΔVpr) or
expressing Vpr (WT). For this purpose, activated primary CD4+ T
cells were infected with CCR5-tropic GFP-marked HIV-1 WT or
ΔVpr virus and the infected pool was separated from the unin-
fected one by ﬂow cytometry on the basis of GFP expression
(Fig. 1A). Sorting efﬁciency was routinely conﬁrmed, immediatelyafter by ﬂow cytometry, and also, following a 10-day co-culture of
the sorted GFP− cells with HIV-1 susceptible SupT1.CCR5.DCSIGN
cells. This co-culture assay ensured that the sorted GFP− pool
contained mostly, if not all, truly uninfected CD4+ T cells (Figs. 1A
and S1). In all cases, immediately after sorting, HIV-1-infected GFP+
cells and virally treated but non-productively infected bystander GFP
− cells (hereafter referred to as uninfected bystander cells or GFP−
cells) were analyzed for ULBP2 mRNA levels by real-time RT-PCR
(Fig. 1A). First, consistent with previous observations (Ward et al.,
2009), we found that ULBP2 mRNA levels in GFP+ HIV-1 WT-
infected CD4+ T cells were markedly higher (∼4.971.00-fold
increase) than those in cells infected with Vpr-deﬁcient virus. In
parallel, a similar analysis of GFP− cells revealed a ∼2.070.17-fold
increase in ULBP2 mRNA abundance in uninfected bystander CD4+ T
cells from cultures infected with HIV-1 WT as compared to their
ΔVpr virus exposed counterparts (Fig. 1B). Similarly, spin-infection
of activated primary CD4+ T cells with GFP-marked HIV-1 viruses
(WT or ΔVpr) pseudotyped with vesicular stomatitis virus G
glycoprotein (VSV-G) revealed an enhanced detection of ULBP2
proteins at the surface of both infected and uninfected bystander
cells, which was Vpr-dependent (Fig. 1C). Thus, these results suggest
that HIV-1 Vpr mediates an upregulation of ULBP2 mRNA and
protein levels in infected as well as in uninfected bystander cells
during ex vivo infection of primary CD4+ T cells.
To further characterize the features of Vpr-induced ULBP2
upregulation on uninfected cells, we made use of the Image
Stream system, a novel tool that allows simultaneous detection
of protein expression by ﬂow cytometry and ﬂuorescence micro-
scopy. Of note, only cells that display high levels of ULBP2 as
detected by ﬂow cytometry could be visualized by the ﬂuores-
cence microscopic feature of the Image Stream (data not shown).
Using this technology we observed the presence of cells harbour-
ing high level of ULBP2 in both infected GFP+ and uninfected
GFP− populations (Fig. 2A). Importantly, we found that the
proportion of ULBP2-high cell in the uninfected GFP− population
was increased (average 1.6 fold) in the context of HIV-1 WT
infection as compared to that of HIV-1-ΔVpr infection (Fig. 2B
and C). This observation was, in essence, consistent with our
earlier ﬂow cytometric data (Fig. 1C), revealing an upregulation
of ULBP2 at the cell surface of uninfected bystander cells that was
Vpr-dependent. As expected, we observed that the GFP+ HIV-1
WT-infected cell population displayed ∼3.6 times more ULBP2-
high cells than the corresponding HIV-1-ΔVpr-infected cell popu-
lation, underscoring once again the positive effect of Vpr on ULBP2
expression (Fig. 2B and C). Collectively, these results indicate that
the frequency of uninfected bystander cells expressing high levels
of ULBP2 is increased upon HIV-1 infection in a Vpr-dependent
manner.
HIV-1-induced upregulation of ULBP2 in uninfected bystander cells
involves virion-associated Vpr
To investigate the involvement of virion-associated Vpr in the
observed augmentation of ULBP2 in uninfected bystander cells, we
next used a previously described virus that expresses a Vpr mutant
(i.e., leucine substitution for phenylalanine at position 23) that is
not incorporated into viral particles, and hereafter, referred to as
HIV-1 Vpr L23F (Yao et al., 1995) (Fig. S2). To this end, we found
that the ∼2-fold increase in ULBP2 mRNA levels typically observed
in uninfected GFP− cells following HIV-1 WT infection (Figs. 1B
and 3A) was essentially abrogated when cells were infected with
HIV-1 Vpr L23F virus (Fig. 3A). Nevertheless, the Vpr-induced
upregulation of ULBP2 expression in the GFP+ population was
comparable between infections with WT and Vpr L23F viruses
(∼3.670.90 and 3.670.82-fold, respectively). Of signiﬁcance, Vpr
L23F is expressed at levels similar to those of Vpr WT in infected
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Fig. 1. HIV-1 infection augments ULBP2 in both infected and uninfected bystander cells in a Vpr-dependent manner. (A–B) Primary CD4+ T cells were infected with CCR5-
tropic GFP-marked HIV-1 WT or ΔVpr viruses. Infected (GFP+) and uninfected (GFP−) cells were sorted for analysis 7 days post-infection and the sorting efﬁciency of GFP-
cells was evaluated immediately after by ﬂow cytometry as well as by co-culture with highly permissive SupT1.CCR5.DCSIGN cells as described in Fig. S1. Total RNA was
extracted from sorted cells and ULBP2 expression was evaluated by real-time RT-PCR. The data were expressed as fold-increase in ULBP2 expression during HIV-1 WT
infection as compared to HIV-1 ΔVpr infection. *Po0.05, ** Po0.01 and *** Po0.005 as determined by unpaired nonparametric Mann–Whitney test. (C) Primary CD4+ T
cells were spin-infected with CCR5-tropic GFP-marked HIV-1 WT or ΔVpr virus pseudotyped with VSV-G and cell-surface ULBP2 was evaluated by ﬂow cytometry on
infected GFP+ and uninfected GFP- cells 4 days post-infection. Mean ﬂuorescence intensity (MFI) values were calculated by subtracting the corresponding isotype control
values. Results shown are representative of data obtained in at least two independent experiments.
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Fig. 2. Vpr increases the proportion of uninfected bystander cells expressing high levels of ULBP2. Primary CD4+ T cells were spin-infected with CCR5-tropic GFP-marked
HIV-1 WT or ΔVpr virus pseudotyped with VSV-G. Four days post-infection, ULBP2 cell-surface levels were evaluated by Image Stream. (A) Microscopic detection of ULBP2-
high GFP+ and ULBP2-high GFP− cells in the context of HIV-1 WT infected cultures using an Image Stream cytometer. (B) Histograms represent the percentage of ULBP-2-
high GFP+ and ULBP2-high GFP− cells in mock, HIV-1WT or HIV-ΔVpr virus-infected cultures. Results shown are representative of data obtained in two independent
experiments. (C) Histograms represent fold increase of ULBP2-high cells in HIV-1 WT infected-cultures relative to HIV-1 ΔVpr-infected cultures. Shown is the average
(7standard deviation) of two independent experiments.
J. Richard et al. / Virology 443 (2013) 248–256250
ULBP2
HIVΔVpr 
HIV WT 
Isotype 
GFP-GFP+
HIV VprL23F 
R
el
at
iv
e 
ce
ll 
nu
m
be
r
R
el
at
iv
e 
ce
ll 
nu
m
be
r
Vpr
Mock 
Mean 3.6 2.2 3.6 0.8
N.S
*
Fo
ld
 in
cr
ea
se
 in
 U
LB
P2
 m
R
N
A 
re
la
tiv
e 
to
 H
IV
-1
 Δ
Vp
r i
nf
ec
tio
n
Fig. 3. HIV-1 Vpr L23F fails to upregulate ULBP2 in uninfected bystander cells. (A-B) Primary CD4+ T cells were infected with CCR5-tropic GFP-marked HIV-1 WT, ΔVpr or
VprL23F virus. (A) Infected GFP+ cells and uninfected GFP− cells were sorted and analyzed for ULBP2 expression by real-time RT-PCR as described in the legend of Fig. 1.
Shown is fold increase in ULBP2 mRNA levels following infection with HIV-1WT or VprL23F virus relative to that obtained following infection with HIV-1ΔVpr virus.
* Po0.05, ** Po0.01, *** Po0.005 and N.S, not signiﬁcant, as determined by unpaired nonparametric Mann–Whitney test. (B) At 4 days post-infection, GFP-expressing cells
were monitored for intracellular expression of Vpr by ﬂow cytometry. (C) Primary CD4+ T cells were spin-infected with CCR5-tropic GFP-marked HIV-1WT, ΔVpr or VprL23F
virus pseudotyped with VSV-G and cell-surface ULBP2 levels were evaluated by ﬂow cytometry on infected GFP+ cells and uninfected GFP− cells, 4 days post-infection. MFI
values were calculated by subtracting the corresponding isotype control values. Results shown are representative of the data obtained in at least two independent
experiments.
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upregulation of cell-surface ULBP2 was observed in uninfected
GFP− cells during HIV-1 Vpr L23F spin-infection (MFI, 18.8 versus
17.3 for HIV-1 ΔVpr or 18.9 for mock-infected), the levels of ULBP2
at the cell surface of the GFP+ population were comparable
between infections with HIV-1 WT and Vpr L23F viruses
(MFI, 57.9 versus 47.2) (Fig. 3C). Importantly, the selective ULBP2
upregulation displayed by the HIV-1 Vpr L23F mutant in GFP+
infected cells provides evidence that the cell sorting system used
to separate infected and uninfected cells is efﬁcient and that
potential cross contaminations do not represent a signiﬁcant
confounding factor. Overall, these results suggest that virion-
associated Vpr, through defective particles or/and abortive infec-
tions, plays an important role in the augmentation of ULBP2 in
uninfected bystander cells during HIV-1 infection of primary CD4+
T cells.
Soluble Vpr induces a DNA damage response
Aside from the two known virion- and cell-associated forms, Vpr
also exists as a soluble molecule that displays natural protein-
transducing properties, raising the possibility that Vpr, in this
capacity, may also transduce uninfected bystander cells. Activation
of ATR by Vpr leads to the formation of DNA repair foci containing γ-
H2AX and 53BP1, which represent early markers of ATR-mediated
DDR (Lai et al., 2005; Zimmerman et al., 2004). To evaluate whether
soluble Vpr possesses a similar ability to induce a DDR, we ﬁrst
examined by confocal microscopy the presence of γ-H2AX- and
53BP1-containing foci in HeLa cells exposed to synthetic Vpr or a
control hemagglutinin (HA) peptide. Cells with more than 10 γ-
H2AX- and/or 53BP1-containing foci were considered positive. As
shown in Fig. 4A, detection of Vpr-transduced cells was observed
down to concentrations as low as 100 ng/ml of soluble Vpr. In that
context, soluble Vpr displayed a nuclear and a perinuclear localiza-
tion as described previously for de novo expressed Vpr (Fig. 4A, Fig.
S3). While some Vpr was also observed in the cytoplasm, this
localization was more pronounced at a higher concentration of
soluble Vpr (1 mg/ml) (Fig. S3). In that regard, it should be men-
tioned that Vpr is a nuclear protein that is capable of shuttling
between the nucleus and the cytoplasm (Sherman et al., 2001), and
that its nuclear and perinuclear localization have been reported to
be important for its G2/M cell cycle arrest-inducing activity (Belzile
et al., 2010a; Sorgel et al., 2012). As quantiﬁed in Fig. 4B, treatmentof cells with soluble Vpr led to an increased detection of cells
containing γ-H2AX (52.2% versus 23.5% for control HA peptide) or
53BP1 foci (45.4% versus 17.7% for control peptide). Similar observa-
tions were made when primary CD4+ T cells were exposed to
soluble Vpr and γ-H2AX expression was evaluated in Vpr-
transduced cells by ﬂow cytometry (Fig. 4C). Importantly, pre-
treatment of soluble Vpr with anti-Vpr antibodies abrogated the
ability of the protein to localize in the nucleus and to induce DDR, as
revealed by the marked reduction in the percentage of cells positive
for γ-H2AX (25.2% versus 45.7% with control Abs) (Fig. S3). The fact
that such treatment did not affect signiﬁcantly the percentage of
cells positive for γ-H2AX in cultures exposed to the control HA
peptide (17.2% versus 21.4% with control Abs), further demonstrates
that the effect of soluble Vpr on DDR is speciﬁc.
Overall, these results provide evidence that soluble Vpr can
induce a DDR, as revealed by the formation of γ-H2AX and 53BP1-
containing DNA repair foci, upon transducing target cells.Soluble Vpr promotes cell cycle arrest and enhances cell-surface
expression of ULBP2 in T cells
Having shown that soluble Vpr induces a DDR, we next asked
whether this form of Vpr could trigger a cell cycle arrest and
increase cell-surface ULBP2 expression in T cells. As evidenced
in Fig. 5A, treatment of primary CD4+ T cells with soluble Vpr
induced a marked increase in the proportion of cells at the G2/M
phase as compared to similar cell populations treated with control
HA peptide (G2/M:G1¼0.74 versus 0.06, respectively). Interest-
ingly, this G2 cell cycle arrest mediated by soluble Vpr was linked
to an augmentation of ULBP2 at the cell surface of treated T cells
(MFI¼42.9 versus 13.4 for HA peptide) (Fig. 5B).
Since similar ﬁndings were obtained in CEM.NKR T cells treated
with soluble Vpr (Fig. 5C and D), we next sought to test in this
cellular system whether the observed cell cycle arrest and up-
regulation of ULBP2 induced by soluble Vpr relied on its ability to
activate a DDR. To this end, CEM.NKR T cells were pre-treated with
caffeine, an inhibitor of the ATR and ATM kinases (Sarkaria et al.,
1999), prior to treatment with soluble Vpr or control HA peptide.
Results from these experiments revealed that the caffeine treat-
ment not only inhibited the cell cycle arrest induced by soluble
Vpr (Fig. 5C) but also markedly reduced the upregulation of ULBP2
at the surface of treated cells (Fig. 5D). Overall, these results
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Fig. 4. Synthetic Vpr induces the formation of DNA repair foci. (A) HeLa cells were treated for 24 h with 100 ng/ml of synthetic Vpr (sVpr) or control HA peptide. Cells were
then ﬁxed, permeabilized, and stained with antibodies against Vpr (red), γ-H2AX (green) and 53BP1 (cyan). DAPI was used to highlight the nuclei (blue). Images were
acquired by confocal microscopy and are representative of multiple ﬁelds. White bars¼10 μm. (B) Histograms represent mean percentage of cells having 410 DNA damage
foci (7standard deviation) from two independent experiments. (C) Primary CD4+ T cells were treated with 10 μg/ml of synthetic Vpr or a control HA synthetic peptide. After
48 h, expression of γ-H2AX was detected in Vpr-transduced cells by intracellular staining with Abs against Vpr and γ-H2AX followed by ﬂow cytometry.
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the activation of a DDR when exposed to target T cells.Discussion
HIV-1 Vpr triggers NK cell mediated lysis of infected cells by
upregulating speciﬁc ligands of the NK receptor, NKG2D, through
activation of the ATR-mediated DDR (Richard et al., 2010; Ward
et al., 2009). Since Vpr is capable of transducing target cells as a
soluble protein or as a virion-associated protein, it was conceivable
that Vpr could act similarly on uninfected bystander cells during
HIV-1 infection. Herein, we demonstrate, for the ﬁrst time, that
Vpr augments ULBP2 expression not only on infected cells but also
on uninfected bystander cells during ex vivo HIV-1 infection of
primary CD4+ T lymphocytes (Fig. 1). Indeed, HIV-1 was found to
increase the frequency of uninfected bystander cells expressing
high levels of ULBP2 in a Vpr-dependent manner (Fig. 2). Given
that these analyses were performed on the total uninfected cell
population and that Vpr is likely to transduce only part of
uninfected cells, we are most probably underestimating the extent
of Vpr-mediated ULBP2 upregulation in bystander cells in the
context of our model system. Unfortunately, ﬂow cytometry
detection of Vpr in the uninfected pool was not sufﬁciently
sensitive to allow the isolation of Vpr-positive cells, most likelyas a result of the low amounts of transduced proteins in
these cells.
Our analysis of whether this enhancement of ULBP2 on unin-
fected bystander cells would be sufﬁcient to drive their lysis by
NK cells revealed no Vpr-dependent killing of uninfected
GFP− cells (data not shown). However, as expected we observed
Vpr-mediated lysis of sorted GFP+ cells, but not of unsorted total
population even though the latter contained more than 25% of GFP
+ cells (data not shown). These results underscore the importance
of cell sorting to precisely evaluate the effect of Vpr in promoting
cell lysis. On this note, given that only part of GFP− cells contain
Vpr, this issue of sorting for Vpr-positive GFP− cells becomes even
more essential in this type of analysis.
Given that a large body of evidence has already clearly demon-
strated that induced expression of NKG2DL triggers lysis of target T
cells by NK cells (Cerboni et al., 2007; Fogli et al., 2008; Norman
et al., 2011; Pham et al., 2011; Richard et al., 2010; Shah et al., 2010;
Ward et al., 2007, 2009), it is conceivable that Vpr-induced
upregulation of ULBP2 on uninfected cells, would render these cells
highly susceptible to NK cell killing. In that regard, HIV-1 encodes
three accessory proteins that all impact the capacity of infected cells
to escape NKG2D-dependent NK cell recognition. Indeed, Nef was
previously shown to downmodulate cell-surface NKG2DL, including
ULBP2 (Cerboni et al., 2007), while Vif-mediated degradation of
APOBEC3G was reported to prevent an optimal Vpr-mediated
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Fig. 5. Synthetic Vpr promotes cell cycle arrest and increases cell-surface ULBP2 expression in T cells. (A–B) Primary CD4+ T cells were treated with 10 μg/ml of synthetic Vpr
(sVpr) or a control HA peptide. (C–D) CEM.NKR T cells were pre-treated with or without 2.5 mM of Caffeine for 1 h prior to treatment with 5 μg/mL of synthetic Vpr (sVpr) or
a control HA peptide. At 48 h (A–C) DNA content and (B–D) ULBP-2 cell-surface expression was evaluated on Vpr-transduced cells by ﬂow cytometry. MFI values were
calculated by subtracting the corresponding isotype control values. Results shown are representative of the data obtained in at least two independent experiments.
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strategy to avoid NK cell recognition is exerted by Vpu, which
downregulates NTB-A, the ligand of the NTB-A co-activation recep-
tor whose engagement is required for NK cells to degranulate when
the activation receptor NKG2D is activated (Shah et al., 2010). In
that context, it is therefore expected that Vpr-transduced unin-
fected bystander cells would display higher level of NKG2D ligands
and superior susceptibility to NK cell-mediated lysis than infected
cells. This might perhaps explain our detection of an upregulation of
ULBP2 in uninfected bystander cells despite the likely transduction
of a limited number of GFP− cells.
This bystander effect of Vpr was found to be entirely abrogated
when infection was performed with virus encoding a mutant of
Vpr that is not packaged into viral particles (Vpr L23F), suggesting
that virion-associated Vpr is entirely responsible for this biological
activity in this infection model system (Fig. 3). This effect of virion-
associated Vpr could be related to the presence of defective viral
particles and/or to abortive infection by WT virus. Indeed, the ratio
of defective to infectious viral particles was reported to be relatively
high during HIV-1-infection in vitro and in vivo (Bourinbaiar, 1994;
Dimitrov et al., 1993; Piatak et al., 1993) and defective particles still
package Vpr (Hrimech et al., 1999; Poon et al., 1998; Richard et al.,
2010). In that context, virion-associated Vpr would be efﬁciently
delivered into uninfected bystander cells by defective particles or
during a non-productive infection, leading to an upregulation of
ULBP2. These results are consistent with previous ﬁndings showing
that Vpr associated with non-infectious or defective particles could
mediate several biological activities, including cell cycle arrest,
apoptosis and induction of cell-surface ULBP2 expression, upon
transduction of target cells (Hrimech et al., 1999; Poon et al., 1998;
Richard et al., 2010).
Although, the data obtained with the HIV-1-Vpr L23F mutant
suggests that virion-associated Vpr is responsible for most of the
ULBP2 upregulation detected in uninfected bystander cells during
ex vivo infection of primary CD4+ T cells, we cannot exclude the
possibility that extracellular Vpr could also contribute to this effectin vivo. Hence, to evaluate whether soluble Vpr could act similarly
on uninfected cells, we tested the effect of synthetic Vpr on
different target cell types. We provide evidence that soluble Vpr
could also mediate the formation of DNA repair foci containing
DNA damage markers γ-H2AX and 53BP1 upon transduction into
target cells (Figs. 4 and S3), indicating that this form of Vpr also
has the ability to induce a DDR. Furthermore, we show that
treatment of T cells with synthetic Vpr is sufﬁcient to promote a
cell cycle arrest and to upregulate cell-surface ULBP2—character-
istics that are known to favour NK cell-mediated T cell lysis (Fig. 5).
Moreover, consistent with previous ﬁndings with de novo
expressed Vpr (Richard et al., 2010; Ward et al., 2009), we provide
evidence that the upregulation of ULBP2 mediated by soluble Vpr
is dependent on the activation of a DDR since this process is
inhibited by caffeine, an inhibitor of ATR and ATM kinases (Fig. 5).
It was previously reported (Hoshino et al., 2007) that Vpr con-
centration in patient plasma was about 10 ng/ml, which represents
an amount that is at least one order of magnitude lower than that
used in the present study. Nevertheless, if one was to take into
consideration the dynamic of HIV replication during the early
stages of infection, the minimal concentration used in the present
study may not appear unrealistically high. Indeed, at early stages
of HIV-1 infection in vivo, viral replication occurs preferentially in
tissues, including the gastrointestinal tract and secondary lym-
phoid organs such as lymph nodes, which indeed display the most
rapid and signiﬁcant CD4+ T cell loss (Brenchley et al., 2004;
Mattapallil et al., 2005; Pantaleo et al., 1991). In that regard, the
frequency of HIV-1-infected mononuclear cells isolated from lym-
phoid tissues was reported to be signiﬁcantly higher (0.5–1 log 10
unit) than that found in the periphery (Pantaleo et al., 1991). In that
context, it is plausible that the concentration of soluble Vpr could be
signiﬁcantly higher than the 10 ng/ml detected in the plasma. In any
case, it is important to mention that at 100 ng/ml, synthetic Vpr was
sufﬁcient to induce DNA repair foci, as detected by immunoﬂuores-
cence (Fig. 4A). In contrast, a higher concentration of synthetic Vpr
was used to evaluate the ability of soluble Vpr to promote a cell cycle
J. Richard et al. / Virology 443 (2013) 248–256254arrest and to enhance cell-surface ULBP2 in T cells (Fig. 5). In fact, this
increased amount of synthetic Vpr was necessary to allow the
detection of Vpr-positive cells by ﬂow cytometry, and was not
unique to our study, as others have also utilized similar doses of
Vpr to investigate the protein biological activities in T cells and
macrophages (Sherman et al., 2002). Given the sensitivity threshold
at which our assays are detecting Vpr-expressing cells, we cannot
rule out the possibility that lower concentrations of synthetic Vpr
would be sufﬁcient to induce similar biological activity in T cells.
However, even though soluble Vpr can induce a DDR and upregulate
ULBP2 when added to T cells, its role in the enhancement of ULBP2
on uninfected bystander cells under natural infection conditions
in vitro appears to be minimal compared to that of virion-associated
Vpr (Fig. 3A and C). These results could be explained by the fact that
host's cell regulates the levels of biologically active soluble Vpr.
Indeed, we have previously reported that Vpr undergoes proteolytic
processing at a very well conserved proprotein convertase (PC)
cleavage site, located within the functionally important C-terminal
arginine-rich domain of the protein (Xiao et al., 2008). Since Vpr
processing occurs extracellularly upon close contact to cells and most
likely involved a cell surface-associated PC, it is the soluble Vpr and
not its virion-associated counterpart that is affected by this process
(Xiao et al., 2008).
Our ﬁndings support a model where Vpr would represent an
additional weapon in the virus' arsenal used to modulate the host's
immune responses. Indeed, Vpr was reported to modulate differ-
ent aspects of the host's immune response, including NK cell
functions, dendritic cell maturation, T cell activation as well as
cytokine and chemokine production (review in (Majumder et al.,
2009)). Our results suggest that Vpr may participate in the killing
of healthy CD4+ T cells, which represent an important arm of the
adaptive immune system, by manipulating the effector killing
function of NK cells during the early phase of the infection when
an expansion and activation of NK cells is observed (Alter et al.,
2007). Hence, our data are in agreement with other recent ﬁndings
that suggest that NK cells would play a role in the killing of
uninfected bystander CD4+ T cells. Indeed, Veillard and colleagues
reported that HIV-1 gp41-triggered expression of speciﬁc ligands
for the activating receptor NKp44 on uninfected bystander cells,
rendered these cells susceptible targets for NK cell-mediated lysis
(Fausther-Bovendo et al., 2009; Vieillard et al., 2005).Conclusion
Taken together, our results reveal that HIV-1 Vpr upregulates
ULBP2 on uninfected bystander T cells, a condition known to
promote NK cell-mediated killing, highlighting a possible involve-
ment of Vpr in the loss of healthy uninfected CD4+ T cells during
HIV-1 infection. These ﬁndings outline an additional mechanism
whereby HIV-1 infection could deplete CD4+ T cells through
chronic activation of NK cells.Materials and methods
Antibodies and reagents
Phytohemagglutinin-L, caffeine and DAPI (49,6-diamidino-2-
phenylindole) were purchased from Sigma-Aldrich (St. Louis, MO,
USA) while human rIL-2 (recombinant interleukin-2) was obtained
from the NIH AIDS Research and Reference Reagent Program
(Lahm and Stein, 1985). The anti-p24 (HB-9725) monoclonal
antibodies (mAbs) were isolated from supernatants of cultured
hybridoma cells obtained from the American Type Culture Collec-
tion (ATCC). The anti-Vpr mouse mAb (8D1) and the rabbitpolyclonal antibodies (pAbs) directed against a pNL4-3 (GenBank:
AAK08485.1) Vpr-derived N-terminal peptide (N-terminal) or the
full Vpr protein (Full) were described previously (Hoshino et al.,
2007; Lavallee et al., 1994). The following commercially available
antibodies were used: rabbit anti-53BP1 (Abcam, Cambridge, MA,
USA), mouse anti-phosphoS139-H2AX (clone JBW301) (Upstate,
Millipore, Billerica, MA, USA) mouse Paciﬁc Blue-conjugated anti-
CD3 mAbs (Clone UCHT1) (Biolegend, San Diego, CA, USA) and
mouse anti-ULBP2 mAbs (R&D Systems, Minneapolis, MN, USA).
All ﬂuorochrome-conjugated secondary antibodies were obtained
from Molecular Probes (Invitrogen, San Diego, CA, USA). The Vpr
synthetic peptide was produced by AnaSpec (Fremont, USA) from
the sequence of HIV-1 pNL4-3 Vpr while the HA synthetic peptide
(YPYDVPDYAK) was produced by the Sheldon Biothechnology
Center (McGill University, Montréal, Québec, Canada). In both
cases, the purity that was achieved exceeded 90%.
Cell lines and isolation of primary cells
HEK 293T, HeLa TZM cells and CEM.NKR T cells were cultured
as described previously (Levesque et al., 2003; Richard et al.,
2010). SupT1.CCR5.DCSIGN cells were a kind gift from Dr. R.
W. Doms (Department of Microbiology, University of Pennsylvania
School of Medicine, Philadelphia, USA) (Laakso et al., 2007). Blood
samples were obtained from consenting HIV-1 and Hepatitis C
Virus seronegative adult donors in accordance with a protocol
approved by the IRCM research ethics review board. Primary CD4+
T lymphocytes were puriﬁed and activated as previously described
(Richard et al., 2010).
Plasmids, proviral DNA constructs and production of HIV-1 viruses
The infectious isogenic CCR5-tropic GFP-marked HIV-1 HxBru.
ADA.GFP (HIV-1WT) and HxBru(Vpr−).ADA.GFP (HIV-1ΔVpr), as
well as the pSVCMV-IN-VSV-G plasmids were previously described
(Belzile et al., 2007; Richard et al., 2010). The CCR5-tropic GFP-
marked HIV-1 HxBru(VprL23F).ADA.GFP (HIV-1VprL23F) proviral
construct was generated by site-directed mutagenesis. HIV-1
infectious viruses were produced in HEK 293T cells and titrated
in HeLa TZM as described previously (Belzile et al., 2007; Levesque
et al., 2003).
Viral infection and sorting of infected/uninfected CD4+ T cells
Infection/spin-infection of activated primary CD4+ T lympho-
cytes was performed as previously described (Levesque et al.,
2003; Richard et al., 2010). For real-time RT-PCR analysis, HIV-1-
infected and uninfected cells were sorted based upon GFP expres-
sion at 7 days post-infection. Sorting efﬁciency was subsequently
conﬁrmed by assessing GFP expression on sorted cells by ﬂow
cytometry immediately after sorting and after a 10-day co-culture
with HIV-1 susceptible SupT1.CCR5.DCSIGN cells at ratio of 1:1. Co-
cultures were stained with Paciﬁc Blue-conjugated anti-CD3 mAb
to distinguish SupT1.CCR5.DCSIGN (CD3 low) from sorted CD4+ T
cells (CD3 high) and the percentage of GFP-positive SupT1.CCR5.
DCSIGN cells was evaluated by ﬂow cytometry.
Detection of cell-surface ULBP2 by ﬂow cytometry and Image stream
Cell surface staining of ULBP2 was performed as previously
described (Richard et al., 2010). For ﬂow cytometry analysis,
ﬂuorescence intensities were acquired using a CyAn™ ADP Analy-
zer (Beckman Coulter, Mississauga, Ontario, Canada) and data
were analyzed using FlowJo software v. 7.25 (Treestar, Ashland,
OR, USA). For image stream analysis, ﬂuorescence intensities and
confocal microscopy images of cells were acquired using an Image
J. Richard et al. / Virology 443 (2013) 248–256 255Stream cytometer (Amnis, Seattle, USA) while data was analyzed
using the Ideas software (Amnis, Seattle, USA).
Intracellular staining and cell cycle analysis by ﬂow cytometry
Cells were ﬁxed for 15 min with 1% PFA and permeabilized for
15 min with cold methanol and 5 min with 0.1% NP40. Cell
samples were then stained for Vpr and/or γ-H2AX using the
anti-Vpr (8D1) mAb or an anti-phosphoS139-H2AX mAb and the
appropriate ﬂuorescence-conjugated secondary mAbs. The DNA
content was then analyzed as previously described (Yao et al.,
1998) on Vpr-positive cells using a Cyan cytometer (Beckman
Coulter). The mathematical model MODFIT was used to calculate
the proportions of cells in the G2/M versus G1 phase of the
cell cycle.
Quantiﬁcation of ULBP2 by real-time RT-PCR
Primary CD4+ T cells were infected with CCR5-tropic GFP-
marked HIV-1WT, HIV-1ΔVpr or HIV-1VprL23F viruses at a multi-
plicity of infection (MOI) of 1. Infected cells were then sorted based
upon GFP expression as described above. ULBP2 expression was
then evaluated by real-time RT-PCR as previously described
(Richard et al., 2010) on sorted GFP+ and GFP− populations. ULBP2
levels were normalized against those of the housekeeping
gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH). A fold
change in expression was calculated using the 2−ΔΔCt formula of
the delta–delta Ct method.
Western blot
HEK293T cells were mock-transfected or transfected with pro-
viral constructs encoding HIV-1WT, HIV-1ΔVpr or HIV-1VprL23F
using a standard calcium phosphate method. Vpr and p24-Gag were
detected in lysates from cells and pelleted virus particles by western
blotting as described previously using mouse anti-p24 mAb and
rabbit anti-Vpr pAb (full) (Belzile et al., 2010b).
Confocal microscopy
Twenty ﬁve thousand HeLa cells were seeded on cover slips in
24-well plates. Cell were then exposed to 100 ng/ml of synthetic
Vpr or a control HA peptide. For blocking experiments, synthetic
Vpr or control HA peptide were pre-treated for 1 h at 4 1C with a
cocktail of anti-Vpr Abs, including mouse anti-Vpr mAb (IgG2A)
(8D1) and rabbit pAbs (N-terminal and Full), or with correspond-
ing control Abs, before addition to HeLa cells (at 1 mg/ml). Twenty-
four hours later, cells were ﬁxed, permeabilized as previously
described (Belzile et al., 2010a), and stained with mouse anti-Vpr
mAb (8D1) and mouse anti-γ-H2AX mAb (IgG1). Cells were then
washed and stained with appropriate anti-mouse secondary
antibodies, while DAPI was used to highlight the nuclei. Images
were acquired and analyzed as previously described (Belzile et al.,
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